p53, erbB-2 and K-ras gene alterations are rare in spontaneous and plutonium-239-induced canine lung neoplasia

Radiation Research

Volumn 145, Issue 2, 1996, Pages 181-187

  Tierney, Lauren A ^a   Hahn, Fletcher F ^a   Lechner, John F ^a  

^a Inhalation Toxicology Research Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLUTONIUM 239; PROTEIN P53;

ADENOSQUAMOUS CARCINOMA; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENERGY TRANSFER; GENE MUTATION; IMMUNOHISTOCHEMISTRY; LUNG CANCER; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTO ONCOGENE; RADIATION CARCINOGENESIS; RADIATION EXPOSURE; SQUAMOUS CELL CARCINOMA; TUMOR SUPPRESSOR GENE;

ALPHA PARTICLES; ANIMALS; CELLS, CULTURED; DOGS; GENES, ERBB-2; GENES, P53; GENES, RAS; IMMUNOENZYME TECHNIQUES; LUNG; LUNG NEOPLASMS; NEOPLASMS, RADIATION-INDUCED; PLUTONIUM; RECEPTOR, ERBB-2; TRACHEA; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0030045304     PISSN: 00337587     EISSN: None     Source Type: Journal    
DOI: 10.2307/3579173     Document Type: Article

References (45)

1. J. M. Samet, The epidemiology of lung cancer. Chest 103, 205-295 (1993).
2. J. M. Samet, Radiation and disease in underground miners. Ann. Am. Conf. Gov. Ind. Hyg. 14, 27-35 (1986).
3. G. Saccomanno, G. C. Huth, O. Auerbach and M. Kuschner, Relationship of radioactive radon daughters and cigarette smoking in the genesis of lung cancer in uranium miners. Cancer 62, 1402-1408 (1988).
4. J. A. Taylor, M. A. Watson, T. R. Devereux, R. Y. Michels, G. Saccomanno and M. Anderson, p53 mutation hotspot in radon-associated lung cancer. Lancet 343, 86-87 (1994).
5. K. H. Vähäkangas, J. M. Samet, R. A. Metcalf, J. A. Welsh, W. P. Bennett, D. P. Lane and C. C. Harris, p53 and ras mutations in radon-associated lung cancer from uranium miners. Lancet 339, 576-580 (1992).
6. J. F. Lechner, S. A. Belinsky, G. Saccomanno, J. M. Samet, W. P. Bennett and L. A. Tierney, Gene aberrations in alpha radiation-caused lung cancer. Am. Rev. Respir. Dis. 147, A331 (1993).
7. G. Farmer, J. Bargonetti, H. Zhu, P. Friedman, R. Prywes and C. Prives, Wild-type p53 activates transcription in vitro. Nature 358, 83-86 (1992).
8. R. Iggo, K. Gatter, J. Bartek, D. Lane and A. L. Harris, Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 335, 675-679 (1990).
9. S. M. Bodner, J. D. Minna, S. M. Jensen, D. D'Amico, D. Carbone, A. F. Gazdar and R. I. Linnoila, Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation. Oncogene 7, 743-749 (1992).
10. I. Chiba, T. Takahashi, M. M. Nav, D. D'Amico, D. T Curiel, T. Mitsudomi, D. L. Buchhagen, D. Carbone, S. Piantadosi, H. Koga, P. T. Reissman, D. J. Slamon, E. C. Holmes and J. D. Minna, Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Oncogene 5, 1603-1610 (1990).
11. L. Recio, S. Sisk, L. Pluta, E. Bermudez, E. A. Gross, Z. Chen, K. Morgan and C. Walker, p53 mutations in formaldehyde-induced nasal squamous cell carcinomas in rats. Cancer Res. 52, 6113-6116 (1992).
12. T. L. Goodrow, R. D. Storer, K. R. Leander, S. R. Prahalada, M. J. van Zwieten and M. O. Bradley, Murine p53 intron sequences 5-8 and their use in polymerase chain reaction/direct sequencing analysis of p53 mutations in CD-1 mouse liver and lung tumors. Mol. Carcinogen. 5, 9-15 (1992).
13. V. I. C. Oreffo, H-W. Lin, P. H. Gumerlock, S. A. Kraegel and H. Witschi, Mutational analysis of a dominant oncogene (c-Ki-ras-2) and a tumor suppressor gene (p53) in hamster lung tumorigenesis. Mol. Carcinogen. 6, 199-202 (1992).
14. G. Kelly, B. L. Stegelmeier and F. F. Hahn, p53 alterations in plutomum-induced F344 rat lung tumors. Radiat. Res. 142, 263-269 (1995).
15. C. C. Harris and M. Hollstein, Clinical implications of the p53 tumor-suppressor gene. N. Engl. J. Med. 329, 1318-1327 (1993).
16. C. I. Bargmann, M-C. Hung and R. A. Weinberg, The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature 319, 226-230 (1986).
17. T. Akiyama, C. Sudo, H. Ogawara, K. Toyoshima and T. Yamamoto, The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science 232, 1644-1646 (1986).
18. neu) in human non-small cell carcinomas of the lung. Cancer Res. 50, 421-425 (1990).
19. D. Shi, H. Gongping, S. Cao, W. Pan, H-Z. Zhang, D. Yu and M-C. Hung, Overexpression of the c-erbB-2/neu-encoded p185 protein in primary lung cancer. Mol. Carcinogen. 5, 213-218 (1992).
20. P. M. Schneider, M-C. Hung, S. M. Chiocca, J. Manning, X. Zhao, K. Fang and J. A. Roth, Differential expression of the c-erbB-2 gene in human small cell and non-small cell lung cancer. Cancer Res. 49, 4968-4971 (1989).
21. neu expression in human lung adenocarcinomas predicts shortened survival. Cancer Res. 50, 5184-5191 (1990).
22. HER2 expression in human non-small cell lung cancer cell lines. Am. J. Respir. Cell Mol. Biol. 6, 359-363 (1992).
23. J. L. Bos, ras oncogenes in human lung cancer: a review. Cancer Res. 49, 4682-4689 (1989).
24. T. Mitsudomi, J. Viallet, J. L. Mulshin, R. I. Linnoila, J. D. Minna and A. F. Gazdar, Mutations of ras genes distinguish a subset of non-small-cell lung cancer cell lines. Oncogene 6, 353-362 (1991).
25. S. Rodenhuis, R. J. C. Slebos, A. J. M. Boot, S. G. Evers, W. T. Mooi, S. S. Wagenaar, P. C. van Bodegon and J. L. Bos, Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung. Cancer Res. 48, 5738-5741 (1988).
26. S. Rodenhuis and R. J. C. Slebos, Clinical significance of ras oncogene activation in human lung cancer. Cancer Res. 52, 2665s-2669s (1992).
27. B. L. Stegelmeier, N. A. Gillett, A. H. Rebar and G. Kelly, The molecular progression of plutonium-239-induced rat lung carcinogenesis: Ki-ras expression and activation. Mol. Carcinogen. 4, 43-51 (1991).
28. S. J. Stowers, P. L. Glover, S. H. Reynolds, L. R. Boone, R. R. Maronpot and M. W. Anderson, Activation of the K-ras proto-oncogene in lung tumors from rats and mice chronically exposed to tetranitromethane. Cancer Res. 47, 3212-3219 (1987).
29. S. A. Belinsky, T. R. Devereux, R. R. Maronpot, G. D. Stoner and M. W. Anderson, Relationship between the formation of promutagenic adducts and the activation of the K-ras proto-oncogene in lung tumors from A/J mice treated with nitrosamines. Cancer Res. 49, 5305-5311 (1989).
30. E. W. Newcomb, L. E. Diamond, S. R. Sloan, M. Corominas, I. Guerrero and A. Pellicer, Radiation and chemical activation of ras oncogenes in different mouse strains. Environ. Health Perspect. 81, 33-37 (1989).
31. S. A. Kraegel, P. H. Gumerlock, D. L. Dungworth, V. I. C. Oreffo and B. R. Madewell, K-ras activation in non-small cell lung cancer in the dog. Cancer Res. 52, 4724-4727 (1992).
32. J. L. Schwartz, J. Rotmensch, R. W. Atcher, R. F. Jostes, F. T. Cross, T. E. Hui, D. Chen, S. Carpenter, H. H. Evans and J. Mencl, Interlaboratory comparison of different alpha-particle and radon sources: cell survival and relative biological effectiveness. Health Phys. 62, 458-461 (1992).
33. R. O. McClellan, B. B. Boecker, F. F. Hahn and B. A. Muggenburg, Lovelace ITRI studies on the toxicity of inhaled radionuclides in beagle dogs. In Life-Span Radiation Effects Studies in Animals: What Can They Tell Us? (R. C. Thompson and J. A. Mahaffey, Eds.), pp. 74-96. CONF-830951, U.S. DOE Technical Information Center, Oak Ridge, TN, 1986.
34. F. F. Hahn, B. A. Muggenburg and W. C. Griffith, Primary lung cancer in the longevity study/control population of the ITRI beagle dog colony. In Inhalation Toxicology Research Institute Annual Report 1991-1992 (G. L. Finch, K. J. Nikula and P. L. Bradley, Eds.), pp. 133-136. LMP-138. National Technical Information Service, Springfield, VA, 1992.
35. H. Stünzi, K. W. Head and S. W. Nielsen, Tumours of the lung. Bull. World Health Org. 50, 9-19 (1974).
36. A. M. Pfeifer, K. E. Cole, D. T. Smoot, A. Weston, J. D. Groopman, P. G. Shields, J-M, Vignaud, M. Tuillerat, M. M. Lipsky, B. F. Trump, J. F. Lechner and C. C. Harris, Simian virus 40 large tumor antigen-immortalized normal human liver epithelial cells express hepatocyte characteristics and metabolize chemical carcinogens. Proc. Natl. Acad. Sci. USA 90, 5123-5157 (1993).
37. T. A. Lehman, W. P. Bennett, R. A. Metcalf, J. A. Welsh, J. Ecker, R. V. Modali, S. Ullrich, J. W. Romano, E. Appela, J. R. Testa, B. I. Gerwin and C. C. Harris, p53 mutations, ras mutations and p53-heat shock 70 protein complexes in human lung carcinoma cell lines. Cancer Res. 51, 4090-4096 (1991).
38. F. Sanger, S. Nicklen and A. R. Loulson, DNA sequencing with chain-terminating inhibitors. Proc. Natl. Acad. Sci. USA 74, 5463-5467 (1977).
39. Y. Kishimoto, Y. Maurakami, M. Shiraishi, K. Hayashi and T. Sekiya, Aberrations of the p53 tumor suppressor gene in human non-small cell carcinomas of the lung. Cancer Res. 52, 4799-4804 (1992).
40. M. Reiss, D. E. Brash, T. Muñoz-Antonia, J. A. Simon, A. Ziegler, V. F. Vellucci and Z. L. Zhou, Status of the p53 tumor suppressor gene in human squamous carcinoma cell lines. Oncol. Res. 4, 349-357 (1992).
41. H. Masuda, C. Miller, H. P. Koeffler, H. Battifora and M. J. Cline, Rearrangement of the p53 gene in human osteogenic sarcomas. Proc. Natl. Acad. Sci. USA 84, 7716-7719 (1987).
42. C. W. Miller, A. Aslo, C. Tsay, D. Slamon, K. Ishizaki, J. Toguchida, T. Yamamuro, B. Lampkin and H. P. Koeffler, Frequency and structure of p53 rearrangements in human osteosarcoma. Cancer Res. 50, 7950-7954 (1990).
43. T. Takahashi, D. D'Amico, I. Chiba, D. L. Buchhan and J. D. Minna, Identification of intronic point mutations as an alternative mechanism for p53 inactivation in lung cancer. J. Clin. Invest. 86, 363-369 (1990).
44. F. S. Leach, T. Tokino, P. Meltzer, M. Burrell, J. D. Oliner, S. Smith, D. E. Hill, D. Sidransky, K. W. Kinder and B. Vogelstein, p53 mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res. 53, 2231-2234 (1993).
45. N. A. Gillett, B. L. Stegelmeier, G. Kelly, P. J. Haley and F. F. Hahn, Expression of epidermal growth factor receptor in plutonium-239-induced lung neoplasms in dogs. Vet. Pathol. 29, 46-52 (1992).